Glaukos Corporation (GKOS) 10-Year Financial Performance & Capital Metrics

GKOS • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.Show more

Revenue $383M +21.9%
EBITDA -$82M +9.1%
Net Income -$146M -8.7%
EPS (Diluted) -2.77 +0.4%
Gross Margin 75.48% -0.7%
EBITDA Margin -21.5% +25.4%
Operating Margin -31.91% +22.0%
Net Margin -38.17% +10.8%
ROE -23.83% +12.3%
ROIC -12.61% -1.0%
Debt/Equity 0.14 -83.4%
Interest Coverage -12.19 -29.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 10.1%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.73%

5Y10.1%

3Y9.26%

TTM30.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM41.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.01%

ROCE

10Y Avg-9.02%

5Y Avg-10.65%

3Y Avg-11.87%

Latest-13.86%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	71.7M	114.4M	159.25M	181.28M	236.98M	224.96M	294.01M	282.86M	314.71M	383.48M
Revenue Growth %	0.57%	0.6%	0.39%	0.14%	0.31%	-0.05%	0.31%	-0.04%	0.11%	0.22%
Cost of Goods Sold+	12.99M	16.18M	21.05M	25.07M	38.59M	91.72M	66.63M	68.98M	75.58M	94.03M
COGS % of Revenue	0.18%	0.14%	0.13%	0.14%	0.16%	0.41%	0.23%	0.24%	0.24%	0.25%
Gross Profit+	58.71M	98.22M	138.2M	156.2M	198.4M	133.24M	227.38M	213.88M	239.14M	289.45M
Gross Margin %	0.82%	0.86%	0.87%	0.86%	0.84%	0.59%	0.77%	0.76%	0.76%	0.75%
Gross Profit Growth %	0.72%	0.67%	0.41%	0.13%	0.27%	-0.33%	0.71%	-0.06%	0.12%	0.21%
Operating Expenses+	69.01M	93.98M	140.49M	169.21M	248.69M	256.79M	260.26M	296.2M	367.84M	411.82M
OpEx % of Revenue	0.96%	0.82%	0.88%	0.93%	1.05%	1.14%	0.89%	1.05%	1.17%	1.07%
Selling, General & Admin	43.96M	64.76M	96.26M	119.53M	176.63M	171.4M	179.26M	192.93M	224.07M	262.85M
SG&A % of Revenue	0.61%	0.57%	0.6%	0.66%	0.75%	0.76%	0.61%	0.68%	0.71%	0.69%
Research & Development	25.05M	29.22M	38.91M	49.68M	68.31M	85.39M	101M	123.27M	138.77M	136.43M
R&D % of Revenue	0.35%	0.26%	0.24%	0.27%	0.29%	0.38%	0.34%	0.44%	0.44%	0.36%
Other Operating Expenses	0	0	5.32M	0	3.75M	0	-20M	-20M	5M	12.55M
Operating Income+	-10.3M	4.24M	-2.28M	-13M	-50.29M	-123.55M	-32.87M	-82.31M	-128.7M	-122.37M
Operating Margin %	-0.14%	0.04%	-0.01%	-0.07%	-0.21%	-0.55%	-0.11%	-0.29%	-0.41%	-0.32%
Operating Income Growth %	0.22%	1.41%	-1.54%	-4.7%	-2.87%	-1.46%	0.73%	-1.5%	-0.56%	0.05%
EBITDA+	-6.03M	8.96M	3.2M	-6.74M	-40.43M	-88.94M	1.55M	-46.37M	-90.72M	-82.44M
EBITDA Margin %	-0.08%	0.08%	0.02%	-0.04%	-0.17%	-0.4%	0.01%	-0.16%	-0.29%	-0.21%
EBITDA Growth %	0.33%	2.49%	-0.64%	-3.1%	-5%	-1.2%	1.02%	-30.93%	-0.96%	0.09%
D&A (Non-Cash Add-back)	4.27M	4.72M	5.48M	6.26M	9.86M	34.61M	34.42M	35.95M	37.98M	39.92M
EBIT	-37.23M	4.24M	1K	-12.37M	-47.47M	-118.2M	-35.9M	-84.71M	-120.09M	-135.56M
Net Interest Income+	-980K	281K	1.38M	2.25M	604K	-11.74M	-12.08M	-11.35M	-4.47M	1.06M
Interest Income	82K	889K	1.38M	2.25M	3.17M	2.38M	1.29M	2.38M	9.16M	11.11M
Interest Expense	1.06M	608K	0	0	2.56M	14.12M	13.37M	13.72M	13.63M	10.04M
Other Income/Expense	-27.99M	324K	2.28M	634K	256K	-8.76M	-16.39M	-16.12M	-5.03M	-23.23M
Pretax Income+	-38.29M	4.57M	1K	-12.37M	-50.04M	-132.31M	-49.27M	-98.43M	-133.73M	-145.6M
Pretax Margin %	-0.53%	0.04%	0%	-0.07%	-0.21%	-0.59%	-0.17%	-0.35%	-0.42%	-0.38%
Income Tax+	33K	43K	93K	583K	-65.46M	-11.97M	326K	766K	934K	771K
Effective Tax Rate %	0.97%	0.99%	-92%	1.05%	-0.31%	0.91%	1.01%	1.01%	1.01%	1.01%
Net Income+	-37.24M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Net Margin %	-0.52%	0.04%	-0%	-0.07%	0.07%	-0.53%	-0.17%	-0.35%	-0.43%	-0.38%
Net Income Growth %	-2.07%	1.12%	-1.02%	-139.77%	2.19%	-8.8%	0.59%	-1%	-0.36%	-0.09%
Net Income (Continuing)	-38.32M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.13	0.12	-0.00	-0.37	0.37	-2.70	-1.07	-2.09	-2.78	-2.77
EPS Growth %	-3.35%	1.06%	-1.02%	-	2%	-8.3%	0.6%	-0.95%	-0.33%	0%
EPS (Basic)	-2.13	0.14	-0.00	-0.37	0.41	-2.70	-1.07	-2.09	-2.78	-2.77
Diluted Shares Outstanding	17.47M	36.46M	34.38M	35.32M	41.15M	44.5M	46.42M	47.44M	48.43M	52.76M
Basic Shares Outstanding	17.47M	32.93M	34.38M	35M	37.35M	44.5M	46.42M	47.44M	48.43M	52.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.14M	120.02M	149.46M	176.57M	262.88M	469.44M	486.13M	443.86M	395.46M	449.79M
Cash & Short-Term Investments	91.12M	95.76M	119.01M	140.49M	173.98M	404.37M	414.05M	352.69M	295.43M	318.92M
Cash Only	21.57M	6.49M	24.51M	29.82M	62.43M	96.6M	100.71M	119.53M	93.47M	169.63M
Short-Term Investments	69.55M	89.27M	94.51M	110.67M	111.55M	307.77M	313.34M	233.17M	201.96M	149.29M
Accounts Receivable	7.55M	14.3M	16.66M	18.67M	38.42M	36.06M	33.44M	36.07M	39.85M	60.74M
Days Sales Outstanding	38.43	45.64	38.17	37.6	59.17	58.51	41.51	46.55	46.22	57.82
Inventory	4.1M	6.84M	11.22M	13.28M	42.58M	15.81M	23.01M	37.84M	41.99M	57.68M
Days Inventory Outstanding	115.14	154.42	194.59	193.34	402.74	62.91	126.06	200.23	202.78	223.9
Other Current Assets	80K	80K	2.57M	4.12M	0	13.21M	15.63M	17.25M	18.19M	12.46M
Total Non-Current Assets+	12.52M	14.35M	16.38M	30.4M	555.52M	536.06M	642.7M	630.31M	544.95M	524.96M
Property, Plant & Equipment	2.15M	7.59M	11.79M	19.15M	91.81M	95.46M	146.13M	166.83M	174.54M	169.94M
Fixed Asset Turnover	33.29x	15.07x	13.50x	9.46x	2.58x	2.36x	2.01x	1.70x	1.80x	2.26x
Goodwill	0	0	0	0	66.13M	66.13M	66.13M	66.13M	66.13M	66.13M
Intangible Assets	10.22M	6.57M	3.15M	0	382.61M	357.69M	332.78M	307.87M	282.96M	263.44M
Long-Term Investments	0	0	0	8.78M	0	9.57M	9.42M	7.08M	0	0
Other Non-Current Assets	149K	188K	1.2M	11.04M	14.97M	7.21M	9.11M	10.61M	21.32M	25.45M
Total Assets+	116.66M	134.37M	165.84M	206.97M	818.4M	1.01B	1.13B	1.07B	940.41M	974.76M
Asset Turnover	0.61x	0.85x	0.96x	0.88x	0.29x	0.22x	0.26x	0.26x	0.33x	0.39x
Asset Growth %	3.48%	0.15%	0.23%	0.25%	2.95%	0.23%	0.12%	-0.05%	-0.12%	0.04%
Total Current Liabilities+	20.36M	16.94M	26.79M	30.36M	57.7M	49.7M	63.36M	72.36M	74.01M	75.13M
Accounts Payable	3.63M	2.97M	6.24M	6.29M	5.78M	4.37M	7.33M	14.4M	13.44M	13.03M
Days Payables Outstanding	101.9	66.94	108.27	91.5	54.68	17.39	40.17	76.21	64.91	50.57
Short-Term Debt	8.93M	0	0	0	0	1.19M	1.01M	430K	0	2.47M
Deferred Revenue (Current)	12K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	516K	883K	95K	115K	13.53M	29.6M	33.81M	35.83M	20.59M	0
Current Ratio	5.11x	7.09x	5.58x	5.81x	4.56x	9.45x	7.67x	6.13x	5.34x	5.99x
Quick Ratio	4.91x	6.68x	5.16x	5.38x	3.82x	9.13x	7.31x	5.61x	4.78x	5.22x
Cash Conversion Cycle	51.67	133.12	124.49	139.43	407.23	104.02	127.4	170.57	184.08	231.15
Total Non-Current Liabilities+	1.11M	159K	846K	2.75M	87.43M	288.35M	478.32M	471.8M	404.63M	132.7M
Long-Term Debt	765K	0	0	0	0	189.42M	280.03M	281.4M	282.77M	0
Capital Lease Obligations	0	0	0	0	72.63M	81.39M	102.35M	101.08M	100.97M	103.4M
Deferred Tax Liabilities	0	0	0	0	9.63M	10.51M	86.45M	79.05M	7.14M	6.93M
Other Non-Current Liabilities	343K	159K	846K	2.75M	5.17M	7.03M	9.49M	10.28M	13.75M	22.37M
Total Liabilities	21.47M	17.1M	27.63M	33.11M	145.13M	338.05M	541.68M	544.16M	478.65M	207.82M
Total Debt+	9.7M	0	0	0	72.63M	272M	383.38M	382.91M	383.74M	105.87M
Net Debt	-11.88M	-6.49M	-24.51M	-29.82M	10.2M	175.4M	282.68M	263.38M	290.27M	-63.75M
Debt / Equity	0.10x	-	-	-	0.11x	0.41x	0.65x	0.72x	0.83x	0.14x
Debt / EBITDA	-	-	-	-	-	-	247.50x	-	-	-
Net Debt / EBITDA	-	-0.72x	-7.66x	-	-	-	182.49x	-	-	-
Interest Coverage	-9.69x	6.98x	-	-	-19.61x	-8.75x	-2.46x	-6.00x	-9.44x	-12.19x
Total Equity+	95.19M	117.27M	138.2M	173.86M	673.27M	667.45M	587.15M	530M	461.77M	766.93M
Equity Growth %	1.59%	0.23%	0.18%	0.26%	2.87%	-0.01%	-0.12%	-0.1%	-0.13%	0.66%
Book Value per Share	5.45	3.22	4.02	4.92	16.36	15.00	12.65	11.17	9.53	14.54
Total Shareholders' Equity	95.19M	117.27M	138.2M	173.86M	673.27M	667.45M	587.15M	530M	461.77M	766.93M
Common Stock	32K	34K	35K	36K	44K	45K	47K	48K	49K	56K
Retained Earnings	-196.61M	-192.09M	-192.18M	-205.13M	-189.71M	-310.06M	-365.21M	-464.41M	-599.07M	-745.44M
Treasury Stock	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K
Accumulated OCI	51K	648K	-591K	738K	1.33M	1M	15K	-2.98M	1.17M	2.62M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.19M	12.31M	25.51M	18.86M	-369K	-22.99M	24.71M	-33.08M	-57.76M	-61.32M
Operating CF Margin %	-0.03%	0.11%	0.16%	0.1%	-0%	-0.1%	0.08%	-0.12%	-0.18%	-0.16%
Operating CF Growth %	0.69%	6.63%	1.07%	-0.26%	-1.02%	-61.3%	2.07%	-2.34%	-0.75%	-0.06%
Net Income	-38.32M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Depreciation & Amortization	4.27M	4.72M	5.48M	6.26M	9.86M	34.61M	34.42M	35.95M	37.98M	39.92M
Stock-Based Compensation	7.89M	8.79M	17.59M	25.7M	0	0	0	0	0	0
Deferred Taxes	27.05M	575K	-925K	1.51M	-66.31M	-12.18M	-1.03M	-54K	-120K	-216K
Other Non-Cash Items	298K	-31K	722K	1.92M	45.12M	78.15M	37.33M	43.67M	49.18M	84.82M
Working Capital Changes	-3.38M	-6.26M	2.73M	-3.58M	-4.47M	-3.22M	3.58M	-13.45M	-10.13M	-39.47M
Change in Receivables	-2.16M	-6.79M	-2.18M	-2.25M	-6.63M	2.24M	1.7M	-3.14M	-3.84M	-21.97M
Change in Inventory	-1.85M	-2.94M	-4.16M	-2.3M	4.08M	1.96M	-7.7M	-15.47M	-4.83M	-18.79M
Change in Payables	1.52M	5.1M	9.23M	771K	779K	-2.68M	12.45M	7.21M	1.3M	21K
Cash from Investing+	-85.63M	-26.12M	-11.73M	-26.4M	43.43M	-205.06M	-58.23M	44.78M	14.1M	47.83M
Capital Expenditures	-877K	-6.28M	-6.31M	-10.31M	-4.72M	-6.93M	-47.78M	-30.27M	-20.25M	-6.3M
CapEx % of Revenue	0.01%	0.05%	0.04%	0.06%	0.02%	0.03%	0.16%	0.11%	0.06%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-15M	-19.84M	-11.7K	-1.24M	-1.61M	-1.82M	-2.08M	-1.01M	-3.17M	-3.15M
Cash from Financing+	107.11M	-1.64M	4.67M	21.58M	-9.64M	262.54M	39.26M	6.25M	15.04M	91.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	115.06M	8.05M	4.67M	21.58M	-5.6M	-3.89M	8.98M	-2.43M	-3.27M	-6.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.06M	6.03M	19.2M	8.55M	-5.09M	-29.92M	-23.08M	-63.35M	-78.01M	-67.62M
FCF Margin %	-0.04%	0.05%	0.12%	0.05%	-0.02%	-0.13%	-0.08%	-0.22%	-0.25%	-0.18%
FCF Growth %	0.62%	2.97%	2.18%	-0.55%	-1.6%	-4.88%	0.23%	-1.75%	-0.23%	0.13%
FCF per Share	-0.18	0.17	0.56	0.24	-0.12	-0.67	-0.50	-1.34	-1.61	-1.28
FCF Conversion (FCF/Net Income)	0.06x	2.72x	-277.26x	-1.46x	-0.02x	0.19x	-0.50x	0.33x	0.43x	0.42x
Interest Paid	834K	285K	0	0	0	0	0	0	0	0
Taxes Paid	25K	513K	12K	401K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-39.12%	4.26%	-0.07%	-8.3%	3.64%	-17.95%	-7.91%	-17.76%	-27.16%	-23.83%
Return on Invested Capital (ROIC)	-9.27%	3.28%	-1.52%	-7.57%	-9.12%	-12.14%	-2.88%	-7.42%	-12.49%	-12.61%
Gross Margin	81.89%	85.86%	86.78%	86.17%	83.72%	59.23%	77.34%	75.61%	75.99%	75.48%
Net Margin	-51.94%	3.95%	-0.06%	-7.14%	6.51%	-53.5%	-16.87%	-35.07%	-42.79%	-38.17%
Debt / Equity	0.10x	-	-	-	0.11x	0.41x	0.65x	0.72x	0.83x	0.14x
Interest Coverage	-9.69x	6.98x	-	-	-19.61x	-8.75x	-2.46x	-6.00x	-9.44x	-12.19x
FCF Conversion	0.06x	2.72x	-277.26x	-1.46x	-0.02x	0.19x	-0.50x	0.33x	0.43x	0.42x
Revenue Growth	57.28%	59.55%	39.21%	13.83%	30.73%	-5.07%	30.7%	-3.79%	11.26%	21.85%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Glaucoma	-	-	-	-	230.97M	-	-	-	-	-
Glaucoma Growth	-	-	-	-	-	-	-	-	-	-
Corneal Health	-	-	-	-	6.02M	-	-	-	-	-
Corneal Health Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	270.09M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	-	-	-	113.39M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	-	-	-	170.8M	144.66M	219.4M	-
United States Growth	-	-	-	-	-	-	-	-15.30%	51.66%	-
International	-	-	-	-	-	-	-	-	95.31M	-
International Growth	-	-	-	-	-	-	-	-	-	-
U	67.7M	105M	140.9M	151.68M	192.46M	133.72M	-	-	-	-
U Growth	-	55.09%	34.20%	7.65%	26.89%	-30.52%	-	-	-	-
Non Us	4M	9.4M	18.35M	29.6M	44.53M	45.64M	-	-	-	-
Non Us Growth	-	134.93%	95.19%	61.30%	50.43%	2.51%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Glaukos Corporation (GKOS) reported $469.8M in revenue for fiscal year 2024. This represents a 19242% increase from $2.4M in 2012.

Glaukos Corporation (GKOS) grew revenue by 21.9% over the past year. This is strong growth.

Glaukos Corporation (GKOS) reported a net loss of $87.6M for fiscal year 2024.

Dividend & Returns

Glaukos Corporation (GKOS) has a return on equity (ROE) of -23.8%. Negative ROE indicates the company is unprofitable.

Glaukos Corporation (GKOS) had negative free cash flow of $27.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Glaukos Corporation (GKOS) 10-Year Financial Performance & Capital Metrics

GKOS • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $383M +21.9%
EBITDA -$82M +9.1%
Net Income -$146M -8.7%
EPS (Diluted) -2.77 +0.4%
Gross Margin 75.48% -0.7%
EBITDA Margin -21.5% +25.4%
Operating Margin -31.91% +22.0%
Net Margin -38.17% +10.8%
ROE -23.83% +12.3%
ROIC -12.61% -1.0%
Debt/Equity 0.14 -83.4%
Interest Coverage -12.19 -29.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 10.1%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.73%

5Y10.1%

3Y9.26%

TTM30.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM41.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.01%

ROCE

10Y Avg-9.02%

5Y Avg-10.65%

3Y Avg-11.87%

Latest-13.86%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	71.7M	114.4M	159.25M	181.28M	236.98M	224.96M	294.01M	282.86M	314.71M	383.48M
Revenue Growth %	0.57%	0.6%	0.39%	0.14%	0.31%	-0.05%	0.31%	-0.04%	0.11%	0.22%
Cost of Goods Sold+	12.99M	16.18M	21.05M	25.07M	38.59M	91.72M	66.63M	68.98M	75.58M	94.03M
COGS % of Revenue	0.18%	0.14%	0.13%	0.14%	0.16%	0.41%	0.23%	0.24%	0.24%	0.25%
Gross Profit+	58.71M	98.22M	138.2M	156.2M	198.4M	133.24M	227.38M	213.88M	239.14M	289.45M
Gross Margin %	0.82%	0.86%	0.87%	0.86%	0.84%	0.59%	0.77%	0.76%	0.76%	0.75%
Gross Profit Growth %	0.72%	0.67%	0.41%	0.13%	0.27%	-0.33%	0.71%	-0.06%	0.12%	0.21%
Operating Expenses+	69.01M	93.98M	140.49M	169.21M	248.69M	256.79M	260.26M	296.2M	367.84M	411.82M
OpEx % of Revenue	0.96%	0.82%	0.88%	0.93%	1.05%	1.14%	0.89%	1.05%	1.17%	1.07%
Selling, General & Admin	43.96M	64.76M	96.26M	119.53M	176.63M	171.4M	179.26M	192.93M	224.07M	262.85M
SG&A % of Revenue	0.61%	0.57%	0.6%	0.66%	0.75%	0.76%	0.61%	0.68%	0.71%	0.69%
Research & Development	25.05M	29.22M	38.91M	49.68M	68.31M	85.39M	101M	123.27M	138.77M	136.43M
R&D % of Revenue	0.35%	0.26%	0.24%	0.27%	0.29%	0.38%	0.34%	0.44%	0.44%	0.36%
Other Operating Expenses	0	0	5.32M	0	3.75M	0	-20M	-20M	5M	12.55M
Operating Income+	-10.3M	4.24M	-2.28M	-13M	-50.29M	-123.55M	-32.87M	-82.31M	-128.7M	-122.37M
Operating Margin %	-0.14%	0.04%	-0.01%	-0.07%	-0.21%	-0.55%	-0.11%	-0.29%	-0.41%	-0.32%
Operating Income Growth %	0.22%	1.41%	-1.54%	-4.7%	-2.87%	-1.46%	0.73%	-1.5%	-0.56%	0.05%
EBITDA+	-6.03M	8.96M	3.2M	-6.74M	-40.43M	-88.94M	1.55M	-46.37M	-90.72M	-82.44M
EBITDA Margin %	-0.08%	0.08%	0.02%	-0.04%	-0.17%	-0.4%	0.01%	-0.16%	-0.29%	-0.21%
EBITDA Growth %	0.33%	2.49%	-0.64%	-3.1%	-5%	-1.2%	1.02%	-30.93%	-0.96%	0.09%
D&A (Non-Cash Add-back)	4.27M	4.72M	5.48M	6.26M	9.86M	34.61M	34.42M	35.95M	37.98M	39.92M
EBIT	-37.23M	4.24M	1K	-12.37M	-47.47M	-118.2M	-35.9M	-84.71M	-120.09M	-135.56M
Net Interest Income+	-980K	281K	1.38M	2.25M	604K	-11.74M	-12.08M	-11.35M	-4.47M	1.06M
Interest Income	82K	889K	1.38M	2.25M	3.17M	2.38M	1.29M	2.38M	9.16M	11.11M
Interest Expense	1.06M	608K	0	0	2.56M	14.12M	13.37M	13.72M	13.63M	10.04M
Other Income/Expense	-27.99M	324K	2.28M	634K	256K	-8.76M	-16.39M	-16.12M	-5.03M	-23.23M
Pretax Income+	-38.29M	4.57M	1K	-12.37M	-50.04M	-132.31M	-49.27M	-98.43M	-133.73M	-145.6M
Pretax Margin %	-0.53%	0.04%	0%	-0.07%	-0.21%	-0.59%	-0.17%	-0.35%	-0.42%	-0.38%
Income Tax+	33K	43K	93K	583K	-65.46M	-11.97M	326K	766K	934K	771K
Effective Tax Rate %	0.97%	0.99%	-92%	1.05%	-0.31%	0.91%	1.01%	1.01%	1.01%	1.01%
Net Income+	-37.24M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Net Margin %	-0.52%	0.04%	-0%	-0.07%	0.07%	-0.53%	-0.17%	-0.35%	-0.43%	-0.38%
Net Income Growth %	-2.07%	1.12%	-1.02%	-139.77%	2.19%	-8.8%	0.59%	-1%	-0.36%	-0.09%
Net Income (Continuing)	-38.32M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.13	0.12	-0.00	-0.37	0.37	-2.70	-1.07	-2.09	-2.78	-2.77
EPS Growth %	-3.35%	1.06%	-1.02%	-	2%	-8.3%	0.6%	-0.95%	-0.33%	0%
EPS (Basic)	-2.13	0.14	-0.00	-0.37	0.41	-2.70	-1.07	-2.09	-2.78	-2.77
Diluted Shares Outstanding	17.47M	36.46M	34.38M	35.32M	41.15M	44.5M	46.42M	47.44M	48.43M	52.76M
Basic Shares Outstanding	17.47M	32.93M	34.38M	35M	37.35M	44.5M	46.42M	47.44M	48.43M	52.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.14M	120.02M	149.46M	176.57M	262.88M	469.44M	486.13M	443.86M	395.46M	449.79M
Cash & Short-Term Investments	91.12M	95.76M	119.01M	140.49M	173.98M	404.37M	414.05M	352.69M	295.43M	318.92M
Cash Only	21.57M	6.49M	24.51M	29.82M	62.43M	96.6M	100.71M	119.53M	93.47M	169.63M
Short-Term Investments	69.55M	89.27M	94.51M	110.67M	111.55M	307.77M	313.34M	233.17M	201.96M	149.29M
Accounts Receivable	7.55M	14.3M	16.66M	18.67M	38.42M	36.06M	33.44M	36.07M	39.85M	60.74M
Days Sales Outstanding	38.43	45.64	38.17	37.6	59.17	58.51	41.51	46.55	46.22	57.82
Inventory	4.1M	6.84M	11.22M	13.28M	42.58M	15.81M	23.01M	37.84M	41.99M	57.68M
Days Inventory Outstanding	115.14	154.42	194.59	193.34	402.74	62.91	126.06	200.23	202.78	223.9
Other Current Assets	80K	80K	2.57M	4.12M	0	13.21M	15.63M	17.25M	18.19M	12.46M
Total Non-Current Assets+	12.52M	14.35M	16.38M	30.4M	555.52M	536.06M	642.7M	630.31M	544.95M	524.96M
Property, Plant & Equipment	2.15M	7.59M	11.79M	19.15M	91.81M	95.46M	146.13M	166.83M	174.54M	169.94M
Fixed Asset Turnover	33.29x	15.07x	13.50x	9.46x	2.58x	2.36x	2.01x	1.70x	1.80x	2.26x
Goodwill	0	0	0	0	66.13M	66.13M	66.13M	66.13M	66.13M	66.13M
Intangible Assets	10.22M	6.57M	3.15M	0	382.61M	357.69M	332.78M	307.87M	282.96M	263.44M
Long-Term Investments	0	0	0	8.78M	0	9.57M	9.42M	7.08M	0	0
Other Non-Current Assets	149K	188K	1.2M	11.04M	14.97M	7.21M	9.11M	10.61M	21.32M	25.45M
Total Assets+	116.66M	134.37M	165.84M	206.97M	818.4M	1.01B	1.13B	1.07B	940.41M	974.76M
Asset Turnover	0.61x	0.85x	0.96x	0.88x	0.29x	0.22x	0.26x	0.26x	0.33x	0.39x
Asset Growth %	3.48%	0.15%	0.23%	0.25%	2.95%	0.23%	0.12%	-0.05%	-0.12%	0.04%
Total Current Liabilities+	20.36M	16.94M	26.79M	30.36M	57.7M	49.7M	63.36M	72.36M	74.01M	75.13M
Accounts Payable	3.63M	2.97M	6.24M	6.29M	5.78M	4.37M	7.33M	14.4M	13.44M	13.03M
Days Payables Outstanding	101.9	66.94	108.27	91.5	54.68	17.39	40.17	76.21	64.91	50.57
Short-Term Debt	8.93M	0	0	0	0	1.19M	1.01M	430K	0	2.47M
Deferred Revenue (Current)	12K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	516K	883K	95K	115K	13.53M	29.6M	33.81M	35.83M	20.59M	0
Current Ratio	5.11x	7.09x	5.58x	5.81x	4.56x	9.45x	7.67x	6.13x	5.34x	5.99x
Quick Ratio	4.91x	6.68x	5.16x	5.38x	3.82x	9.13x	7.31x	5.61x	4.78x	5.22x
Cash Conversion Cycle	51.67	133.12	124.49	139.43	407.23	104.02	127.4	170.57	184.08	231.15
Total Non-Current Liabilities+	1.11M	159K	846K	2.75M	87.43M	288.35M	478.32M	471.8M	404.63M	132.7M
Long-Term Debt	765K	0	0	0	0	189.42M	280.03M	281.4M	282.77M	0
Capital Lease Obligations	0	0	0	0	72.63M	81.39M	102.35M	101.08M	100.97M	103.4M
Deferred Tax Liabilities	0	0	0	0	9.63M	10.51M	86.45M	79.05M	7.14M	6.93M
Other Non-Current Liabilities	343K	159K	846K	2.75M	5.17M	7.03M	9.49M	10.28M	13.75M	22.37M
Total Liabilities	21.47M	17.1M	27.63M	33.11M	145.13M	338.05M	541.68M	544.16M	478.65M	207.82M
Total Debt+	9.7M	0	0	0	72.63M	272M	383.38M	382.91M	383.74M	105.87M
Net Debt	-11.88M	-6.49M	-24.51M	-29.82M	10.2M	175.4M	282.68M	263.38M	290.27M	-63.75M
Debt / Equity	0.10x	-	-	-	0.11x	0.41x	0.65x	0.72x	0.83x	0.14x
Debt / EBITDA	-	-	-	-	-	-	247.50x	-	-	-
Net Debt / EBITDA	-	-0.72x	-7.66x	-	-	-	182.49x	-	-	-
Interest Coverage	-9.69x	6.98x	-	-	-19.61x	-8.75x	-2.46x	-6.00x	-9.44x	-12.19x
Total Equity+	95.19M	117.27M	138.2M	173.86M	673.27M	667.45M	587.15M	530M	461.77M	766.93M
Equity Growth %	1.59%	0.23%	0.18%	0.26%	2.87%	-0.01%	-0.12%	-0.1%	-0.13%	0.66%
Book Value per Share	5.45	3.22	4.02	4.92	16.36	15.00	12.65	11.17	9.53	14.54
Total Shareholders' Equity	95.19M	117.27M	138.2M	173.86M	673.27M	667.45M	587.15M	530M	461.77M	766.93M
Common Stock	32K	34K	35K	36K	44K	45K	47K	48K	49K	56K
Retained Earnings	-196.61M	-192.09M	-192.18M	-205.13M	-189.71M	-310.06M	-365.21M	-464.41M	-599.07M	-745.44M
Treasury Stock	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K
Accumulated OCI	51K	648K	-591K	738K	1.33M	1M	15K	-2.98M	1.17M	2.62M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.19M	12.31M	25.51M	18.86M	-369K	-22.99M	24.71M	-33.08M	-57.76M	-61.32M
Operating CF Margin %	-0.03%	0.11%	0.16%	0.1%	-0%	-0.1%	0.08%	-0.12%	-0.18%	-0.16%
Operating CF Growth %	0.69%	6.63%	1.07%	-0.26%	-1.02%	-61.3%	2.07%	-2.34%	-0.75%	-0.06%
Net Income	-38.32M	4.52M	-92K	-12.95M	15.42M	-120.35M	-49.59M	-99.19M	-134.66M	-146.37M
Depreciation & Amortization	4.27M	4.72M	5.48M	6.26M	9.86M	34.61M	34.42M	35.95M	37.98M	39.92M
Stock-Based Compensation	7.89M	8.79M	17.59M	25.7M	0	0	0	0	0	0
Deferred Taxes	27.05M	575K	-925K	1.51M	-66.31M	-12.18M	-1.03M	-54K	-120K	-216K
Other Non-Cash Items	298K	-31K	722K	1.92M	45.12M	78.15M	37.33M	43.67M	49.18M	84.82M
Working Capital Changes	-3.38M	-6.26M	2.73M	-3.58M	-4.47M	-3.22M	3.58M	-13.45M	-10.13M	-39.47M
Change in Receivables	-2.16M	-6.79M	-2.18M	-2.25M	-6.63M	2.24M	1.7M	-3.14M	-3.84M	-21.97M
Change in Inventory	-1.85M	-2.94M	-4.16M	-2.3M	4.08M	1.96M	-7.7M	-15.47M	-4.83M	-18.79M
Change in Payables	1.52M	5.1M	9.23M	771K	779K	-2.68M	12.45M	7.21M	1.3M	21K
Cash from Investing+	-85.63M	-26.12M	-11.73M	-26.4M	43.43M	-205.06M	-58.23M	44.78M	14.1M	47.83M
Capital Expenditures	-877K	-6.28M	-6.31M	-10.31M	-4.72M	-6.93M	-47.78M	-30.27M	-20.25M	-6.3M
CapEx % of Revenue	0.01%	0.05%	0.04%	0.06%	0.02%	0.03%	0.16%	0.11%	0.06%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-15M	-19.84M	-11.7K	-1.24M	-1.61M	-1.82M	-2.08M	-1.01M	-3.17M	-3.15M
Cash from Financing+	107.11M	-1.64M	4.67M	21.58M	-9.64M	262.54M	39.26M	6.25M	15.04M	91.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	115.06M	8.05M	4.67M	21.58M	-5.6M	-3.89M	8.98M	-2.43M	-3.27M	-6.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.06M	6.03M	19.2M	8.55M	-5.09M	-29.92M	-23.08M	-63.35M	-78.01M	-67.62M
FCF Margin %	-0.04%	0.05%	0.12%	0.05%	-0.02%	-0.13%	-0.08%	-0.22%	-0.25%	-0.18%
FCF Growth %	0.62%	2.97%	2.18%	-0.55%	-1.6%	-4.88%	0.23%	-1.75%	-0.23%	0.13%
FCF per Share	-0.18	0.17	0.56	0.24	-0.12	-0.67	-0.50	-1.34	-1.61	-1.28
FCF Conversion (FCF/Net Income)	0.06x	2.72x	-277.26x	-1.46x	-0.02x	0.19x	-0.50x	0.33x	0.43x	0.42x
Interest Paid	834K	285K	0	0	0	0	0	0	0	0
Taxes Paid	25K	513K	12K	401K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-39.12%	4.26%	-0.07%	-8.3%	3.64%	-17.95%	-7.91%	-17.76%	-27.16%	-23.83%
Return on Invested Capital (ROIC)	-9.27%	3.28%	-1.52%	-7.57%	-9.12%	-12.14%	-2.88%	-7.42%	-12.49%	-12.61%
Gross Margin	81.89%	85.86%	86.78%	86.17%	83.72%	59.23%	77.34%	75.61%	75.99%	75.48%
Net Margin	-51.94%	3.95%	-0.06%	-7.14%	6.51%	-53.5%	-16.87%	-35.07%	-42.79%	-38.17%
Debt / Equity	0.10x	-	-	-	0.11x	0.41x	0.65x	0.72x	0.83x	0.14x
Interest Coverage	-9.69x	6.98x	-	-	-19.61x	-8.75x	-2.46x	-6.00x	-9.44x	-12.19x
FCF Conversion	0.06x	2.72x	-277.26x	-1.46x	-0.02x	0.19x	-0.50x	0.33x	0.43x	0.42x
Revenue Growth	57.28%	59.55%	39.21%	13.83%	30.73%	-5.07%	30.7%	-3.79%	11.26%	21.85%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Glaucoma	-	-	-	-	230.97M	-	-	-	-	-
Glaucoma Growth	-	-	-	-	-	-	-	-	-	-
Corneal Health	-	-	-	-	6.02M	-	-	-	-	-
Corneal Health Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	270.09M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	-	-	-	113.39M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	-	-	-	170.8M	144.66M	219.4M	-
United States Growth	-	-	-	-	-	-	-	-15.30%	51.66%	-
International	-	-	-	-	-	-	-	-	95.31M	-
International Growth	-	-	-	-	-	-	-	-	-	-
U	67.7M	105M	140.9M	151.68M	192.46M	133.72M	-	-	-	-
U Growth	-	55.09%	34.20%	7.65%	26.89%	-30.52%	-	-	-	-
Non Us	4M	9.4M	18.35M	29.6M	44.53M	45.64M	-	-	-	-
Non Us Growth	-	134.93%	95.19%	61.30%	50.43%	2.51%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Glaukos Corporation (GKOS) reported $469.8M in revenue for fiscal year 2024. This represents a 19242% increase from $2.4M in 2012.

Glaukos Corporation (GKOS) grew revenue by 21.9% over the past year. This is strong growth.

Glaukos Corporation (GKOS) reported a net loss of $87.6M for fiscal year 2024.

Dividend & Returns

Glaukos Corporation (GKOS) has a return on equity (ROE) of -23.8%. Negative ROE indicates the company is unprofitable.

Glaukos Corporation (GKOS) had negative free cash flow of $27.6M in fiscal year 2024, likely due to heavy capital investments.